Corcept Therapeutics Incorporated
CORT
Rangering i aksjer
#1694
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo... Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Aksjekurs
$116.44
Markedsverdi
$12.59B
Endring (1 dag)
3.87%
Endring (1 år)
48.14%
Land
US
Handel Corcept Therapeutics Incorporated (CORT)
Kategori
Healthcare
Antall utestående aksjer for Corcept Therapeutics Incorporated (CORT)
Antall utestående aksjer per June 2026: 105.38M
Ifølge Corcept Therapeutics Incorporated sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 105.38M. Ved slutten av December 2023 hadde selskapet 103.56M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Corcept Therapeutics Incorporated (CORT) fra 2001 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 105.38M | 2.08% |
| 2024 | 103.23M | -0.32% |
| 2023 | 103.56M | -3.02% |
| 2022 | 106.79M | -7.67% |
| 2021 | 115.65M | 0.21% |
| 2020 | 115.41M | 0.93% |
| 2019 | 114.35M | -9.02% |
| 2018 | 125.68M | 10.71% |
| 2017 | 113.53M | 2.68% |
| 2016 | 110.57M | 3.53% |
| 2015 | 106.80M | 5.77% |
| 2014 | 100.98M | 1.16% |
| 2013 | 99.82M | 7.31% |
| 2012 | 93.02M | 11.65% |
| 2011 | 83.31M | 21.91% |
| 2010 | 68.34M | 30.31% |
| 2009 | 52.44M | 12.25% |
| 2008 | 46.72M | 36.41% |
| 2007 | 34.25M | 49.95% |
| 2006 | 22.84M | 1.03% |
| 2005 | 22.61M | 22.60% |
| 2004 | 18.44M | 113.17% |
| 2003 | 8.65M | 28.73% |
| 2002 | 6.72M | 25.00% |
| 2001 | 5.38M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 445.06M | 322.35% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 18.05B | 17,027.57% |
HK
|
